What is competition in the pharmaceutical industry?
Effective competition means that companies producing pharmaceuticals, healthcare devices, or other health-related products and services compete with one another based on the quality and price of their products and services..
What is the competition law in Japan?
Japanese competition law consists of the Antimonopoly Act (独占禁止法, Dokusen Kinshihō, "AMA"), officially the Act on Prohibition of Private Monopolization and Maintenance of Fair Trade (私的独占の禁止及び公正取引の確保に関する法律, Shiteki-dokusen no Kinshi oyobi Kōseitorihiki no Kakuho ni Kansuru Hōritsu, Act No..
What is the Japanese competition law?
Japanese competition law consists of the Antimonopoly Act (独占禁止法, Dokusen Kinshihō, "AMA"), officially the Act on Prohibition of Private Monopolization and Maintenance of Fair Trade (私的独占の禁止及び公正取引の確保に関する法律, Shiteki-dokusen no Kinshi oyobi Kōseitorihiki no Kakuho ni Kansuru Hōritsu, Act No..
What is the pharmaceutical affairs law in Japan?
The objective of this law is to regulate matters necessary for securing the quality, efficacy and safety of pharmaceuticals, quasi-drugs (Iyaku-bugaihin), cosmetics and medical devices, while taking necessary steps to promote research and development of pharmaceuticals and medical devices in high necessity, and thereby .
What is the pharmaceutical regulatory body of Japan?
PMDA (Pharmaceuticals and Medical Devices Agency) is Japanese regulatory agency, working together with Ministry of Health, Labour and Welfare..
Why is competition high in the pharmaceutical industry?
Competition is important because it compels industry to provide higher quality goods and services at lower prices.
In the pharmaceutical industry, competition can motivate brand companies to create new and improved medicines and encourage generic companies to offer less expensive alternatives..
- Competition is important because it compels industry to provide higher quality goods and services at lower prices.
In the pharmaceutical industry, competition can motivate brand companies to create new and improved medicines and encourage generic companies to offer less expensive alternatives. - indirect purpose of the antimonopoly laws.
The first of these is the familiar prohibition of conduct which would be destructive of free and fair competition.
Three types of conduct are prohibited: (1) private monopolization, (2) unreasonable trade restraints, and (3) unfair business practices. - Japan is the third largest pharmaceutical market in the world and a critical export market for U.S. pharmaceuticals.
Since 2013, the Government of Japan (“GOJ”) has promoted the healthcare industry as an important growth engine under the country's economic revitalization and growth strategy. - The ICH is essentially composed of six parties: the three major regulatory authorities of the USA, Europe, and Japan, and the three corresponding associations of pharmaceutical manufacturers.
